Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Engineered Gut Bacteria Show Potential as a New Weapon Against Pancreatic Cancer
    25 July 2026

    Engineered Gut Bacteria Show Potential as a New Weapon Against Pancreatic Cancer

    Engineered Gut Bacteria Show Potential as a New Weapon Against Pancreatic CancerResearchers have developed a genetically engineered probiotic bacterium that could offer a promising new approach for treating pancreatic cancer, one of the deadliest forms of cancer with limited therapeutic options. The study demonstrates that a modified strain of Bifidobacterium longum, a naturally occurring gut bacterium, can selectively colonize pancreatic tumors and stimulate a potent anti-tumor immune response.

  • Akums Enters Color Cosmetics Manufacturing with Strategic Acquisition of Oriflame India’s Production Facilities
    25 July 2026
    Akums Enters Color Cosmetics Manufacturing with Strategic Acquisition of Oriflame India’s Production Facilities

    Akums Drugs & Pharmaceuticals Ltd., India's leading Contract Development and Manufacturing Organization (CDMO), has announced the acquisition of Oriflame India's manufacturing business, marking its entry into the fast-growing color cosmetics manufacturing sector while significantly expanding its personal care and wellness portfolio.

  • FDA Approves First 12-Hour OTC Pain Relief Tablet Combining Acetaminophen and Naproxen
    25 July 2026
    FDA Approves First 12-Hour OTC Pain Relief Tablet Combining Acetaminophen and Naproxen

    The U.S. Food and Drug Administration (FDA) has approved Tylenol with Naproxen, the first nonprescription fixed-dose combination of acetaminophen and naproxen sodium for up to 12 hours of pain relief. The approval introduces a new over-the-counter (OTC) option for consumers seeking long-lasting, dual-action pain management without a prescription.

  • EU Panel Backs Roche’s Susvimo, Opening New Era for Continuous AMD Treatment
    24 July 2026
    EU Panel Backs Roche’s Susvimo, Opening New Era for Continuous AMD Treatment

    Roche has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Susvimo® (ranibizumab) for the treatment of neovascular age-related macular degeneration (nAMD). If the European Commission grants final approval, Susvimo will become the first continuous drug-delivery treatment for nAMD in the European Union.

  • US FDA Warns Almon Healthcare Over Serious API GMP Lapses
    24 July 2026
    US FDA Warns Almon Healthcare Over Serious API GMP Lapses

    The U.S. Food and Drug Administration (US FDA) has issued a Warning Letter to Almon Healthcare Private Limited, Ahmedabad, Gujarat, after identifying significant violations of Current Good Manufacturing Practice (CGMP) regulations at its active pharmaceutical ingredient (API) manufacturing facility during an inspection conducted from February 9–13, 2026. The warning letter was issued on July 13, 2026.

  • Novo Nordisk Files Lawsuit Against Eli Lilly Over GLP-1 Drug Advertisements
    22 July 2026
    Novo Nordisk Files Lawsuit Against Eli Lilly Over GLP-1 Drug Advertisements

    Novo Nordisk has announced that it has filed a lawsuit against Eli Lilly and Company in the United States, alleging that Lilly's advertising campaigns for its GLP-1 medicines are misleading and do not present complete scientific information.

  • US FDA Issues Warning Letter to Alembic Pharmaceuticals Over Clinical Study Consent Process
    22 July 2026
    US FDA Issues Warning Letter to Alembic Pharmaceuticals Over Clinical Study Consent Process
    The US Food and Drug Administration (FDA) has issued a Warning Letter to Alembic Pharmaceuticals Ltd. after identifying deficiencies during an inspection of the company's bioequivalence research facility in Vadodara, Gujarat. The inspection was conducted between March 3 and March 7, 2025, as part of the FDA's Bioresearch Monitoring Program.
  • Sanofi Publicly Reprimanded by UK Pharma Watchdog After Pfizer Complaint
    22 July 2026
    Sanofi Publicly Reprimanded by UK Pharma Watchdog After Pfizer Complaint

    Global pharmaceutical company Sanofi has received a Public Reprimand from the Prescription Medicines Code of Practice Authority (PMCPA) after a complaint was filed by Pfizer.

    The PMCPA investigated the case (CASE/0689/08/25) and found that Sanofi had breached several rules of the 2024 ABPI Code of Practice, which sets standards for how pharmaceutical companies should promote their medicines in the UK.

  • ICMR Transfers Three Indigenous Biomedical Technologies to Indian Industry for Cancer and Vaccine Development
    21 July 2026
    ICMR Transfers Three Indigenous Biomedical Technologies to Indian Industry for Cancer and Vaccine Development

    The Indian Council of Medical Research (ICMR) has transferred three indigenous healthcare technologies to leading Indian pharmaceutical and vaccine manufacturers for further development, manufacturing, and commercialization. The initiative is aimed at accelerating affordable healthcare solutions while strengthening the country's self-reliance in medical innovation.

  • USFDA Issues One Observation After Routine cGMP Inspection at Cipla's InvaGen Facility in New York
    21 July 2026
    USFDA Issues One Observation After Routine cGMP Inspection at Cipla's InvaGen Facility in New York

    Cipla Limited has informed the stock exchanges that the United States Food and Drug Administration (USFDA) conducted a routine current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility of its wholly owned subsidiary, InvaGen Pharmaceuticals Inc., located in Central Islip, Long Island, New York, USA.

    The inspection was carried out from July 13 to July 17, 2026 (EDT) as part of the USFDA's routine regulatory oversight of pharmaceutical manufacturing facilities.

Subscribe to Pharma News